14 June 2018 - Afternoon meeting - Login for venue
The European Medicines Agency (EMA) is making preparations to ensure that it can continue to protect public and animal health in the EU after the UK leaves on 30 March 2019. One of the consequences of Brexit is that the EMA will relocate to Amsterdam in the Netherlands, where it plans to be operational by 30 March 2019. The EMA is working on the assumption that the UK will become a ‘third country’ as of 30 March 2019. This unprecedented change raises a number of concerns for UK healthcare and supplier industries including whether the UK will be ready to take over the role of the EMA in the UK, the timely availability of new medicines, potential border issues for urgently required medicines, harmonisation of standards, pricing issues and more. Our expert panel will comment on and discuss some of the political, legal, and healthcare pitfalls that may arise and how they might be addressed.
· John Cassels – Partner, Fieldfisher LLP
· Dr Paul Willimas MP – Member of the Health and Social Care Select Committee
· Emma Du Four – Head of International Regulatory Policy and Intelligence, AbbVie, and Vice-Chair, Regulatory Affairs Advisory Committee, BioIndustry Association
Sponsors: Fieldfisher LLP